Welcome to our dedicated page for Greenwich Lifesciences SEC filings (Ticker: GLSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Greenwich LifeSciences, Inc. filings document the reporting, governance, and public-company controls of a clinical-stage biopharmaceutical issuer developing GLSI-100 through the FLAMINGO-01 breast cancer recurrence program. Recent disclosures include a Form 12b-25 notice for a delayed annual report, proxy materials for the annual meeting, and Form 8-K reports on stockholder voting results.
The filing record also covers auditor appointment and change matters, board-election proposals, ratification of the independent registered public accounting firm, and internal-control disclosures referenced in accounting-firm transition materials.
Greenwich LifeSciences will hold its Annual Meeting on December 18, 2025 at 9:00 a.m. local time in New York to elect five directors and ratify MaloneBailey LLP as independent auditor for fiscal 2025.
The record date is October 28, 2025, with 13,854,539 shares outstanding; a quorum requires 6,927,270 shares represented. Directors are elected by a plurality of votes cast, while auditor ratification requires a majority of shares present and entitled to vote.
Ownership is concentrated: CEO Snehal Patel beneficially owns 6,074,953 shares (41.11%); all directors and officers as a group hold 51.47%. 2024 CEO compensation totaled $6,241,685, including stock awards of $5,322,841. The Audit Committee dismissed RBSM and engaged MaloneBailey on July 19, 2025; 2024 audit fees were $64,000 and audit-related fees were $88,000.